Transmedics Group, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2021
November 09, 2021 at 04:05 pm EST
Share
TransMedics Group, Inc. provided earnings guidance for the fourth quarter and Full Year 2021, for the quarter, The company expects revenue to be in the range of $7 million to $8 million as company refocused the organization on company commercial efforts and begin to see initial contribution from OCS heart and liver commercial revenues.
For the full year 2021. The company expects net revenue for the full-year 2021 to be in the range of $27.6 million to $28.6 million, which represents 8% to 12% growth compared to the company's prior year net revenue.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
TRANSMEDICS GROUP, INC. 
